|
KMID : 1036020230120010037
|
|
지질.동맥경화학회지
2023 Volume.12 No. 1 p.37 ~ p.46
|
|
|
New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
|
|
Kim Kyung-An
Park Hun-Jun
|
|
|
Abstract
|
|
|
|
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). There are abundant and unequivocal data to indicate that low-density lipoproteins (LDL) are a cause of ASCVD. Reduction of plasma low-density lipoprotein cholesterol (LDL-C) by medical therapy such as statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have proven to significantly reduce the risk of cardiovascular events. However, for many reasons, many patients are not able to achieve LDL-C levels recommended by guidelines on currently available therapies. This has led to the development of new drugs lowering LDL-C, such as inclisiran, bempedoic acid, and evinacumab, in the hope of reducing cardiovascular (CV) risk. Drugs targeting lipoprotein (a) (Lp[a]) also have a role in the prevention of atherosclerosis, with genetic studies having established that 20%?30% of the human population inherits plasma Lp(a) levels in the atherogenic range. In this paper, we will review the recent progress made in the approaches to LDL-C and Lp(a) therapeutic modulation.
|
|
|
KEYWORD
|
|
|
Atherosclerosis, Low density lipoprotein cholesterol, Lipoprotein (a), Therapeutics, Cardiovascular diseases
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|